• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Effect of very small tumor size on cancer-specific mortality in node-positive breast cancer.非常小的肿瘤大小对淋巴结阳性乳腺癌患者癌症特异性死亡率的影响。
J Clin Oncol. 2011 Jul 1;29(19):2619-27. doi: 10.1200/JCO.2010.29.5907. Epub 2011 May 23.
2
Breast Cancer-Specific Mortality in Small-Sized Tumor with Stage IV Breast Cancer: A Population-Based Study.四期乳腺癌中肿瘤体积小患者的乳腺癌特异性死亡率:一项基于人群的研究。
Oncologist. 2021 Feb;26(2):e241-e250. doi: 10.1002/onco.13567. Epub 2020 Nov 3.
3
Effect of large tumor size on cancer-specific mortality in node-negative breast cancer.大肿瘤大小对淋巴结阴性乳腺癌患者癌症特异性死亡率的影响。
Mayo Clin Proc. 2012 Dec;87(12):1171-80. doi: 10.1016/j.mayocp.2012.07.023.
4
Breast cancer-specific mortality in small-sized tumor with node-positive breast cancer: a nation-wide study in Korean breast cancer society.小肿瘤伴淋巴结阳性乳腺癌的乳腺癌特异性死亡率:韩国乳腺癌协会的一项全国性研究
Breast Cancer Res Treat. 2016 Oct;159(3):489-98. doi: 10.1007/s10549-016-3943-4. Epub 2016 Sep 2.
5
Effect of tumor size on breast cancer-specific survival stratified by joint hormone receptor status in a SEER population-based study.在一项基于监测、流行病学和最终结果(SEER)人群的研究中,肿瘤大小对按联合激素受体状态分层的乳腺癌特异性生存的影响。
Oncotarget. 2015 Sep 8;6(26):22985-95. doi: 10.18632/oncotarget.3945.
6
Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis: implication for extended endocrine therapy.诊断后五年内雌激素受体阳性乳腺癌女性的乳腺癌特异性死亡率风险:延长内分泌治疗的意义。
J Clin Endocrinol Metab. 2012 Dec;97(12):E2201-9. doi: 10.1210/jc.2012-2423. Epub 2012 Sep 19.
7
Effect of lymph node metastasis size on breast cancer-specific and overall survival in women with node-positive breast cancer.淋巴结转移大小对淋巴结阳性乳腺癌女性患者乳腺癌特异性生存和总生存的影响。
Breast Cancer Res Treat. 2015 Jul;152(1):209-216. doi: 10.1007/s10549-015-3451-y. Epub 2015 Jun 4.
8
Different patterns in the prognostic value of age for breast cancer-specific mortality depending on hormone receptor status: a SEER population-based analysis.根据激素受体状态,年龄对乳腺癌特异性死亡率的预后价值存在不同模式:一项基于监测、流行病学和最终结果(SEER)人群的分析。
Ann Surg Oncol. 2015 Apr;22(4):1102-10. doi: 10.1245/s10434-014-4108-5. Epub 2014 Sep 24.
9
The effect of local therapy on breast cancer-specific mortality of women with occult breast cancer and advanced nodal disease (N2/N3): a population analysis.局部治疗对隐匿性乳腺癌伴局部晚期淋巴结转移(N2/N3)女性的乳腺癌特异性死亡率的影响:一项人群分析。
Breast Cancer Res Treat. 2019 Aug;177(1):155-164. doi: 10.1007/s10549-019-05285-x. Epub 2019 May 24.
10
Does a Positive Axillary Lymph Node Needle Biopsy Result Predict the Need for an Axillary Lymph Node Dissection in Clinically Node-Negative Breast Cancer Patients in the ACOSOG Z0011 Era?在ACOSOG Z0011时代,腋窝淋巴结针吸活检结果为阳性能否预测临床腋窝淋巴结阴性的乳腺癌患者是否需要进行腋窝淋巴结清扫?
Ann Surg Oncol. 2016 Apr;23(4):1123-8. doi: 10.1245/s10434-015-4944-y. Epub 2015 Nov 9.

引用本文的文献

1
Clinical Implication of Subcategorizing T2 Category in Metaplastic Breast Cancer.化生性乳腺癌中T2亚分类的临床意义
J Breast Cancer. 2025 Jun;28(3):193-205. doi: 10.4048/jbc.2025.0032.
2
Breast cancer histopathology, classification and clinical management: Current perspectives.乳腺癌组织病理学、分类及临床管理:当前观点
Bioinformation. 2024 Dec 31;20(12):2069-2079. doi: 10.6026/9732063002002069. eCollection 2024.
3
Prediction of axillary lymph node metastasis in T1 breast cancer using diffuse optical tomography, strain elastography and molecular markers.利用扩散光学层析成像、应变弹性成像和分子标志物预测T1期乳腺癌腋窝淋巴结转移
Quant Imaging Med Surg. 2025 Mar 3;15(3):2162-2174. doi: 10.21037/qims-24-1664. Epub 2025 Feb 26.
4
Real-World Evidence of the Impact of CanAssist Breast on Physician's Decision About the Use of Adjuvant Chemotherapy in Early Breast Cancer.CanAssist Breast对早期乳腺癌辅助化疗使用决策影响的真实世界证据。
Cureus. 2024 Dec 12;16(12):e75622. doi: 10.7759/cureus.75622. eCollection 2024 Dec.
5
Collagen signature adds prognostically significant information to staging for breast cancer.胶原蛋白特征为乳腺癌分期增添了具有预后意义的信息。
ESMO Open. 2024 Dec;9(12):103990. doi: 10.1016/j.esmoop.2024.103990. Epub 2024 Nov 21.
6
Hub metastatic gene signature and risk score of breast cancer patients with small tumor sizes using WGCNA.基于 WGCNA 的小肿瘤大小乳腺癌患者瘤内转移基因特征和风险评分。
Breast Cancer. 2024 Nov;31(6):1114-1129. doi: 10.1007/s12282-024-01627-w. Epub 2024 Aug 27.
7
Unveiling the best predictive models for early‑onset metastatic cancer: Insights and innovations (Review).揭示早期转移性癌症最佳预测模型:洞察与创新(综述)。
Oncol Rep. 2024 Apr;51(4). doi: 10.3892/or.2024.8719. Epub 2024 Mar 8.
8
Exploration of the relationship between tumor-infiltrating lymphocyte score and histological grade in breast cancer.探讨乳腺癌肿瘤浸润淋巴细胞评分与组织学分级的关系。
BMC Cancer. 2024 Mar 7;24(1):318. doi: 10.1186/s12885-024-12069-0.
9
Incidence and risk factors of lymph node metastasis in breast cancer patients without preoperative chemoradiotherapy and neoadjuvant therapy: analysis of SEER data.未接受术前放化疗和新辅助治疗的乳腺癌患者淋巴结转移的发生率及危险因素:监测、流行病学与最终结果(SEER)数据的分析
Gland Surg. 2023 Nov 24;12(11):1508-1524. doi: 10.21037/gs-23-258. Epub 2023 Nov 17.
10
The expression of high mobility group protein 3 () in breast cancer with emphasis on its role in lymphovascular invasion.高迁移率族蛋白3()在乳腺癌中的表达,重点关注其在淋巴管浸润中的作用。 (注:原文中“high mobility group protein 3”后括号内内容缺失)
Am J Cancer Res. 2023 Nov 15;13(11):5334-5351. eCollection 2023.

本文引用的文献

1
Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group.西南肿瘤协作组随机临床试验患者中癌症生存率的种族差异。
J Natl Cancer Inst. 2009 Jul 15;101(14):984-92. doi: 10.1093/jnci/djp175. Epub 2009 Jul 7.
2
Underlying causes of the black-white racial disparity in breast cancer mortality: a population-based analysis.乳腺癌死亡率中黑人和白人种族差异的潜在原因:一项基于人群的分析。
J Natl Cancer Inst. 2009 Jul 15;101(14):993-1000. doi: 10.1093/jnci/djp176. Epub 2009 Jul 7.
3
Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century.根据雌激素受体状态分析早期乳腺癌的复发模式:二十五年的治疗靶点
Breast Cancer Res Treat. 2009 Sep;117(2):319-24. doi: 10.1007/s10549-008-0282-0. Epub 2009 Jan 10.
4
Seeding and propagation of untransformed mouse mammary cells in the lung.未转化的小鼠乳腺细胞在肺中的接种与增殖。
Science. 2008 Sep 26;321(5897):1841-4. doi: 10.1126/science.1161621. Epub 2008 Aug 28.
5
Systemic spread is an early step in breast cancer.全身扩散是乳腺癌的早期阶段。
Cancer Cell. 2008 Jan;13(1):58-68. doi: 10.1016/j.ccr.2007.12.003.
6
Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis.美国根据雌激素受体状态和诊断时年龄划分的乳腺癌死亡率趋势。
J Clin Oncol. 2007 May 1;25(13):1683-90. doi: 10.1200/JCO.2006.09.2106. Epub 2007 Apr 2.
7
Is cancer a disease of self-seeding?癌症是一种自我播种的疾病吗?
Nat Med. 2006 Aug;12(8):875-8. doi: 10.1038/nm0806-875.
8
Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status.非裔美国人和美国白人乳腺癌患者生存情况的荟萃分析:种族与社会经济地位的比较
J Clin Oncol. 2006 Mar 20;24(9):1342-9. doi: 10.1200/JCO.2005.03.3472.
9
Effect of screening and adjuvant therapy on mortality from breast cancer.筛查与辅助治疗对乳腺癌死亡率的影响。
N Engl J Med. 2005 Oct 27;353(17):1784-92. doi: 10.1056/NEJMoa050518.
10
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.早期乳腺癌化疗和激素治疗对复发及15年生存率的影响:随机试验综述
Lancet. 2005;365(9472):1687-717. doi: 10.1016/S0140-6736(05)66544-0.

非常小的肿瘤大小对淋巴结阳性乳腺癌患者癌症特异性死亡率的影响。

Effect of very small tumor size on cancer-specific mortality in node-positive breast cancer.

机构信息

Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA 02115, USA.

出版信息

J Clin Oncol. 2011 Jul 1;29(19):2619-27. doi: 10.1200/JCO.2010.29.5907. Epub 2011 May 23.

DOI:10.1200/JCO.2010.29.5907
PMID:21606424
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3139369/
Abstract

PURPOSE

Traditionally, larger tumor size and increasing lymph node (LN) involvement have been considered independent predictors of increased breast cancer-specific mortality (BCSM). We sought to characterize the interaction between tumor size and LN involvement in determination of BCSM. In particular, we evaluated whether very small tumor size may predict for increased BCSM relative to larger tumors in patients with extensive LN involvement.

PATIENTS AND METHODS

Using Surveillance, Epidemiology and End Results registry data, we identified 50,949 female patients diagnosed between 1990 and 2002 with nonmetastatic T1/T2 invasive breast cancer treated with surgery and axillary LN dissection. Primary study variables were tumor size, degree of LN involvement, and their corresponding interaction term. Kaplan-Meier methods, adjusted Cox proportional hazards models with interaction terms, and a linear trend test across nodal categories were performed.

RESULTS

Median follow-up was 99 months. In multivariable analysis, there was significant interaction between tumor size and LN involvement (P < .001). Using T1aN0 as reference, T1aN2+ conferred significantly higher BCSM compared with T1bN2+ (hazard ratio [HR], 20.66 v 12.53; P = .02). A similar pattern was seen among estrogen receptor (ER) -negative patients with T1aN2+ compared with T1bN2+ (HR, 24.16 v 12.67; P = .03), but not ER-positive patients (P = .52). The effect of very small tumor size on BCSM was intermediate among N1 cancers, between that of N0 and N2+ cancers.

CONCLUSION

Very small tumors with four positive LNs may predict for higher BCSM compared with larger tumors. In extensive node-positive disease, very small tumor size may be a surrogate for biologically aggressive disease. These results should be validated in future database studies.

摘要

目的

传统上,较大的肿瘤大小和淋巴结(LN)受累程度增加被认为是乳腺癌特异性死亡率(BCSM)增加的独立预测因素。我们试图描述肿瘤大小和 LN 受累程度之间的相互作用,以确定 BCSM。特别是,我们评估了在广泛 LN 受累的患者中,非常小的肿瘤大小相对于较大的肿瘤是否可以预测 BCSM 增加。

方法

使用监测、流行病学和最终结果(SEER)登记处的数据,我们确定了 50949 名在 1990 年至 2002 年期间诊断为非转移性 T1/T2 浸润性乳腺癌的女性患者,这些患者接受了手术和腋窝淋巴结清扫术治疗。主要研究变量是肿瘤大小、LN 受累程度及其相应的交互项。进行了 Kaplan-Meier 方法、具有交互项的调整 Cox 比例风险模型和线性趋势检验。

结果

中位随访时间为 99 个月。在多变量分析中,肿瘤大小和 LN 受累之间存在显著的相互作用(P <.001)。使用 T1aN0 作为参考,T1aN2+ 与 T1bN2+相比,BCSM 显著更高(风险比 [HR],20.66 v 12.53;P =.02)。在雌激素受体(ER)阴性患者中也观察到类似的模式,T1aN2+与 T1bN2+相比,BCSM 更高(HR,24.16 v 12.67;P =.03),但在 ER 阳性患者中则不然(P =.52)。在 N1 癌症中,非常小的肿瘤大小对 BCSM 的影响处于 N0 和 N2+癌症之间。

结论

与较大的肿瘤相比,有四个阳性淋巴结的非常小的肿瘤可能预示着更高的 BCSM。在广泛的淋巴结阳性疾病中,非常小的肿瘤大小可能是生物学侵袭性疾病的替代指标。这些结果应在未来的数据库研究中得到验证。